
|Videos|December 20, 2021
Making a lasting impact with sustained drug delivery in glaucoma
Author(s)David Hutton
Ahmad Aref, MD, and Paul Singh, MD, offer a recap of their EyeCon 2021 presentation.
Advertisement
As ophthalmologists treat patients, drug compliance is always a concern, especially when a patient may be required to use drops daily. During the Ophthalmology Times® EyeCon 2021 program, Ahmad Aref, MD, and Paul Singh, MD, presented “Making a Lasting Impact With Sustained Drug Delivery in Glaucoma,” detailing some options available today. They offer a recap of that presentation.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


